Abstract Introduction: Chronic pain (CP) affects 35.0%–51.3% of the UK population, with 67%–88% reporting sleep disturbances. Cannabis‐based medicinal products (CBMPs)…
Abstract The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal…
Abstract Introduction: The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for…
Abstract This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety…
Abstract Background: Research on cannabis‐based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high‐quality evidence. Studies…
Abstract Aim: This study aims to analyze the health‐related quality of life (HRQoL) and safety outcomes in attention‐deficit/hyperactivity disorder (ADHD)…
Abstract Introduction: While there is increasing evidence of the effects of cannabis‐based medicinal products (CBMPs) on health‐related quality of life…
Abstract Rationale: Cannabis-based medicinal products (CBMPs) have been identified as novel therapeutics for generalised anxiety disorder (GAD) based on pre-clinical…
Abstract Introduction: : There are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze…
Abstract Background There is a paucity of high-quality evidence of the efficacy and safety of cannabis-based medicinal products in treatment…